Sweden's Nanexa Q1 revenue falls, loss widens

Nanexa AB

29/04/2026 07:19

Overview

Sweden drug delivery tech firm's Q1 revenue fell yr/yr, operating loss widened

Q1 net loss increased from prior year, with EPS at SEK -0.08

Company reported strong preclinical results for monthly and quarterly semaglutide dosing

Outlook

Company did not provide specific guidance or outlook for future quarters or the full year

Result Drivers

PRECLINICAL PROGRESS - Co reported strong preclinical results for monthly and quarterly semaglutide dosing

Company press release: ID:nMFNb5T7zN

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 1.63 mln
Q1 EPS
-SEK 0.08
Q1 Net Income
-SEK 14.02 mln
Q1 EBIT
-SEK 13.61 mln


Analyst Coverage

The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 33 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)